SCHEMBL15210514

SCHEMBL15210514

NS(=O)(=O)c1cccc(Nc2nc3c(-c4ccccc4-c4ccccc4)nccn3n2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 10/20 0.53
JAK3 P52333 10/20 0.53
CDK1 P06493 8/20 0.53
PTK2 Q05397 6/20 0.53
CDK2 P24941 5/20 0.53
CDK5 Q00535 4/20 0.53
SYK P43405 3/20 0.53
AURKA O14965 3/20 0.53
DCLK1 O15075 3/20 0.53
AURKB Q96GD4 3/20 0.53
PDPK1 O15530 2/20 0.53
ROCK2 O75116 2/20 0.53
PRKD3 O94806 2/20 0.53
MAP4K4 O95819 2/20 0.53
EGFR P00533 2/20 0.53
NTRK1 P04629 2/20 0.53
PRKCG P05129 2/20 0.53
LCK P06239 2/20 0.53
FYN P06241 2/20 0.53
LYN P07948 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15212684 0.89 JAK2 (0.53) JAK2JAK3CDK1PTK2CDK2
SCHEMBL16394451 0.83 JAK2 (0.49) JAK2JAK3PTK2AURKAKDR
SCHEMBL15212854 0.81 JAK2 (0.67) JAK2JAK3PTK2
SCHEMBL15221147 0.81 CDK1 (0.52) JAK2JAK3CDK1PTK2CDK2
SCHEMBL15210810 0.80 JAK2 (0.58) JAK2JAK3CDK1PTK2FLT4
SCHEMBL15210580 0.80 CDK1 (0.65) JAK2JAK3CDK1PTK2CDK2
SCHEMBL19982892 0.77 JAK2 (0.44) JAK2JAK3PTK2SYK
SCHEMBL15221201 0.77 JAK2 (0.60) JAK2JAK3PTK2CAMK2D
SCHEMBL15212646 0.77 JAK2 (0.55) JAK2JAK3PTK2SYKAURKA
SCHEMBL15210689 0.77 JAK2 (0.41) JAK2JAK3PTK2SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 US claimed
EP-2817310-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4]TRIAZOLO [1, 5 -A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS Merck Patent GmbH (DE) 2014-12-31 EP claimed
WO-2013124026-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2013-08-29 WO claimed
EP-2817310-B1 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2018-03-21 EP disclosed
EP-2817310-B1 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2018-03-21 EP disclosed
US-9120804-B2 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors MERCK PATENT GMBH (DE) 2015-09-01 US disclosed
US-9120804-B2 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors MERCK PATENT GMBH (DE) 2015-09-01 US disclosed
US-9120804-B2 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors MERCK PATENT GMBH (DE) 2015-09-01 US disclosed
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 US disclosed
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 US disclosed
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 US disclosed
WO-2013124026-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2013-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS SYK, EIF2AK4, BTK JAK2 29/4885JAK3 127/4885CDK1 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.